With aligned missions dedicated to furthering the impact of science for the benefit of society, we have partnered with Frontiers Journals, a leading open access publisher and open science platform, on various projects this year. Through this fruitful collaboration, we assembled global thought leaders and innovators for broad discussions on how to integrate science, medicine, technology and society to envision a better future. Covering diverse topics, these ePanels and videos are provided free to the community on the VKS platform and Frontiers website, and aim to spur progressive ideas and ongoing conversations that will shape the interface between research, healthcare and public health.
The Promise of AI in Pandemic Times ePanel
Bringing together AI luminaries with diverse perspectives on AI in medicine and public health, this collaborative ePanel explored how AI technologies and approaches can be deployed to tackle health challenged posed by the COVID-19 pandemic. Panelists from across academic, industry and legal perspectives discussed the vast opportunities for AI in epidemiology, drug discovery, predictive modeling of outbreaks, diagnosis of medical scans and more. Equally important, the conversation addressed significant hurdles for the field, and how to overcome them to successfully implement AI solutions in pandemic times.
The live event concluded with a dynamic audience Q/A, where field leaders answered questions from global audiences in real-time, and was followed by a networking lounge hosted by Keystone Symposia, for attendees to engage with each other from around the world and continue these important conversations about the future of AI in medicine and public health.
Reflecting on the 100th Anniversary of the Discovery of Insulin
This year marked the 100th anniversary of the discovery and successful purification of insulin, pioneering the way for many important milestones of modern endocrinology. To commemorate this important anniversary for the research community, Keystone Symposia and Frontiers Journals collaborated on a special ePanel discussion featuring field leaders, past and present, to reflect on the evolution of the field and explore future directions. The discussion featured “Diabetes: Many Faces of the Disease” eSymposia co-organizers Dr. Lori Sussel and Dr. Juleen Zierath on how this discovery shaped the field as it is today, and where new horizons lie in personalizing diabetes treatments.
Policy Labs- Discussions at the Intersection of Science & Society
This year has brought to the forefront of global awareness the importance of scientific research for informing public health policies, but also revealed many unexpected challenges in doing so.
These conversations between global experts and thought leaders address how we can better leverage science as a tool to guide policy decisions that benefit society.
Focusing on issues that arose during the COVID-19 pandemic, the discussions look to apply these lessons learned to broader medical and societal challenges by identifying current systemic barriers to effective science-driven policy making, and approaches to improve cross-sector communication and collaboration.
Policy Making in the Context of the COVID-10 Response, with Sir Peter Gluckman of the International Network for Government Science Advice
The Mechanisms and Interface Between Science & Policymaking at the International Level, with Sir Peter Gluckman of the International Network for Government Science Advice
The Profound & Radical Change COVID-19 Brought to the Science-Policy Nexus, with Robert-Jan Smits, President of the Executive Board, Eindhoven University of Technology
Scientific Response to the COVID-19 Virus, with James Wilsdon, of The Research on Research Institute
Shannon Weiman earned her PhD in Biomedical Sciences from the University of California, San Diego, specializing in microbiology and immunology. Prior to joining the Keystone Symposia team, she worked as a freelance writer for leaders in academic, industry and government research, including Stanford University’s Biomedical Innovation Initiative, the University of Colorado’s Biofrontiers Program, UCSF, the FDA and the American Society for Microbiology.